Dermatology Times' Weekly Crossword: August 10, 2025

Welcome to Dermatology Times' Weekly Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

This week's special edition of the Dermatology Times crossword focuses on he recent approval of delgocitinib for adults with moderate to severe CHE who have not responded adequately to prior topical corticosteroids or for whom corticosteroid use is not advisable.¹

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the week.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

3.Top country involved in the DELTA trials besides the US.

4.Delgocitinib inhibits how many JAK isoforms?

7.This clinical trial assessed long-term safety and efficacy of delgocitinib.

9.This condition is characterized by relapsing or persistent hand eczema for more than 3 months.

10.This dermatologist called delgocitinib “a first-in-class topical therapy poised to simplify our approach to CHE.”

13.Brand name of delgocitinib cream approved for CHE in 2025.

15.According to Gooderham et al. 2025, what was the most common non-infectious adverse event reported during DELTA 3?

Down

1.Trial design type for DELTA 3.

2.This JAK inhibitor is the first topical treatment FDA-approved for CHE.

5.Patients with which two IGA-CHE scores were not treated during DELTA 3 unless relapse occurred? (Answer format: “__ or __”)

6.The severity of CHE was assessed using this index.

8.First region outside the US where delgocitinib was approved.

11.Delgocitinib cream is applied how many times per day?

12.The 2025 medical meeting where post hoc data on delgocitinib was presented.

14.This symptom, alongside pain, was significantly reduced by delgocitinib.

16.This metric measured treatment success in the DELTA trials.